NVAX Novavax Inc

Price (delayed)

$19.4

Market cap

$1.52B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$19.49

Enterprise value

$579.94M

Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III ...

Highlights
The revenue has grown by 9% YoY but it has contracted by 8% from the previous quarter
Novavax's equity has shrunk by 156% YoY
Novavax's net income has plunged by 55% YoY and by 12% from the previous quarter

Key stats

What are the main financial stats of NVAX
Market
Shares outstanding
78.22M
Market cap
$1.52B
Enterprise value
$579.94M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.45
Earnings
Revenue
$1.29B
EBIT
-$1.43B
EBITDA
-$1.26B
Free cash flow
-$813.92M
Per share
EPS
-$19.49
Free cash flow per share
-$10.42
Book value per share
-$5.34
Revenue per share
$16.52
TBVPS
$31.93
Balance sheet
Total assets
$2.62B
Total liabilities
$3.04B
Debt
$448.43M
Equity
-$416.95M
Working capital
-$20.24M
Liquidity
Debt to equity
-1.08
Current ratio
0.99
Quick ratio
0.73
Net debt/EBITDA
0.74
Margins
EBITDA margin
-97.7%
Gross margin
77.8%
Net margin
-114.3%
Operating margin
-108.9%
Efficiency
Return on assets
-55.7%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-305.9%
Return on sales
-110.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVAX stock price

How has the Novavax stock price performed over time
Intraday
4.3%
1 week
-3.19%
1 month
-36.16%
1 year
-89.12%
YTD
-86.44%
QTD
6.59%

Financial performance

How have Novavax's revenue and profit performed over time
Revenue
$1.29B
Gross profit
$1B
Operating income
-$1.41B
Net income
-$1.48B
Gross margin
77.8%
Net margin
-114.3%
Novavax's net income has plunged by 55% YoY and by 12% from the previous quarter
Novavax's operating income has plunged by 51% YoY and by 11% from the previous quarter
Novavax's net margin has decreased by 42% YoY and by 22% QoQ
The operating margin has declined by 38% year-on-year and by 20% since the previous quarter

Growth

What is Novavax's growth rate over time

Valuation

What is Novavax stock price valuation
P/E
N/A
P/B
N/A
P/S
1.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.45
Novavax's EPS has decreased by 40% YoY and by 10% QoQ
Novavax's equity has shrunk by 156% YoY
NVAX's P/S is 94% below its 5-year quarterly average of 18.1 and 84% below its last 4 quarters average of 7.3
The revenue has grown by 9% YoY but it has contracted by 8% from the previous quarter

Efficiency

How efficient is Novavax business performance
Novavax's return on sales has decreased by 41% YoY and by 22% QoQ
NVAX's return on assets is down by 16% year-on-year and by 13% since the previous quarter

Dividends

What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVAX.

Financial health

How did Novavax financials performed over time
Novavax's total assets is 14% lower than its total liabilities
The total liabilities has soared by 52% year-on-year and by 10% since the previous quarter
NVAX's quick ratio is down by 45% year-on-year and by 20% since the previous quarter
Novavax's equity has shrunk by 156% YoY
NVAX's debt to equity has dropped by 116% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.